Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company d...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Website: www.tonixpharma.com

Address:

200 Connell Drive, Suite 3100, Berkeley Heights, United States

CIOBRAN Apr. 28 at 2:02 PM

$TNXP WE ARE DOING REALLY BADLY AND IT'S DIFFICULT FOR ME TO UNDERSTAND, EVEN IF THERE ARE NO HUGE SALES OF TONMYA, COMPARED TO LAST YEAR WE HAVE POTENTIALLY MORE STRENGTH IN THE FUTURE.

1 · Reply

Diegodelavega33 Apr. 28 at 1:48 PM

$TNXP Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry Verrry

0 · Reply

TheUnmaker Apr. 28 at 1:45 PM

$TNXP BUY TFing dip you monkeys!

0 · Reply

StockJayC Apr. 28 at 1:44 PM

$TNXP SJS recently entering with a new position!

0 · Reply

Rungreen Apr. 28 at 1:19 PM

$TNXP Wall Street Zen—what a joke!!!!

1 · Reply

Sammy2425 Apr. 28 at 1:15 PM

$TNXP the Seth ATM. Just try and find a worse chart than this. 19 cash grabs to keep the lights on over the last decade. And guess what. There are a few more on the way.

0 · Reply

Sammy2425 Apr. 28 at 1:10 PM

$TNXP sub 5.00. Seth is burning cash again. Rinse and repeat. Gotta keep the lights on at expense of the common. 17th dilution incoming

0 · Reply

Willy_Nilly Apr. 28 at 1:08 PM

$TNXP

0 · Reply

Stino715pro Apr. 28 at 12:36 PM

$TNXP to Time, if someone is saying to you that you have to jump in the river, you will do that! 1 week it is sell Tonix and 2 day’s later you have to buy snd them sell again, seriously 😧

0 · Reply

Pipipopopipi Apr. 28 at 12:36 PM

$TNXP another 3% down and it’s not even open yet. Must be because strait of hormutz, chat gpt slowdown or opec news!!!. Just normal

0 · Reply

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Apr 15, 2026, 7:00 AM EDT - 13 days ago

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Mar 31, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026

Mar 26, 2026, 7:00 AM EDT - 4 weeks ago

Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain

Mar 23, 2026, 4:32 PM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026

Mar 18, 2026, 4:58 PM EDT - 5 weeks ago

Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026

Mar 17, 2026, 4:35 PM EDT - 5 weeks ago

Tonix Pharmaceuticals Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026

Mar 13, 2026, 7:10 AM EDT - 6 weeks ago

Tonix Pharmaceuticals Says Prescriptions For Chronic Pain Drug Top 4,200 Since Launch

Mar 12, 2026, 5:30 PM EDT - 6 weeks ago

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 11, 2026, 1:00 PM EDT - 6 weeks ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Forum

Mar 10, 2026, 8:00 AM EDT - 7 weeks ago

Tonix Pharmaceuticals Presented Post Hoc Analyses of Phase 3 Data on TONMYATM at the 8th International Congress on Controversies in Fibromyalgia

Mar 9, 2026, 4:30 PM EDT - 7 weeks ago

Tonix Pharmaceuticals Presented Data on TONMYA™ in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 9, 2026, 4:30 PM EDT - 7 weeks ago

Tonix Pharmaceuticals Presented Data on TONMYATM in Treating Patients with Fibromyalgia at the 2026 AAPM PainConnect Annual Meeting

Mar 5, 2026, 4:15 PM EST - 7 weeks ago

Tonix Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Studies of TONMYA™ and Prototype Formulations in the Journal Clinical Pharmacology in Drug Development

Mar 4, 2026, 11:10 AM EST - 7 weeks ago

Tonix Pharmaceuticals Holding Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 4:30 PM EST - 7 weeks ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting

Mar 3, 2026, 7:04 AM EST - 2 months ago

Tonix Pharmaceuticals Stock Dips After Nasdaq Uplisting

Mar 3, 2026, 6:00 AM EST - 2 months ago

Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market

Feb 25, 2026, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals to Participate in Two Investor Conferences in March

Jan 30, 2026, 7:00 AM EST - 3 months ago

Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit

Jan 6, 2026, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 4 months ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 5 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 13, 2025, 10:00 AM EST - 5 months ago

Tonix Pharmaceuticals Holding Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 4:15 PM EST - 6 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 6 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Sep 30, 2025, 8:30 AM EDT - 7 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 18, 2025, 8:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 17, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Sep 4, 2025, 1:35 PM EDT - 8 months ago

Tonix Pharmaceuticals Holding Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Tonix Pharmaceuticals Holding Transcript: FDA Announcement

Aug 15, 2025, 3:50 PM EDT - 9 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 9 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 9 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 10 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Mar 13, 2025, 3:30 PM EDT - 1 year ago

Tonix Pharmaceuticals Holding Transcript: Life Sciences Virtual Investor Conference

CIOBRAN Apr. 28 at 2:02 PM

$TNXP WE ARE DOING REALLY BADLY AND IT'S DIFFICULT FOR ME TO UNDERSTAND, EVEN IF THERE ARE NO HUGE SALES OF TONMYA, COMPARED TO LAST YEAR WE HAVE POTENTIALLY MORE STRENGTH IN THE FUTURE.

1 · Reply

Diegodelavega33 Apr. 28 at 1:48 PM

0 · Reply

TheUnmaker Apr. 28 at 1:45 PM

$TNXP BUY TFing dip you monkeys!

0 · Reply

StockJayC Apr. 28 at 1:44 PM

$TNXP SJS recently entering with a new position!

0 · Reply

Rungreen Apr. 28 at 1:19 PM

$TNXP Wall Street Zen—what a joke!!!!

1 · Reply

Sammy2425 Apr. 28 at 1:15 PM

$TNXP the Seth ATM. Just try and find a worse chart than this. 19 cash grabs to keep the lights on over the last decade. And guess what. There are a few more on the way.

0 · Reply

Sammy2425 Apr. 28 at 1:10 PM

$TNXP sub 5.00. Seth is burning cash again. Rinse and repeat. Gotta keep the lights on at expense of the common. 17th dilution incoming

0 · Reply

Willy_Nilly Apr. 28 at 1:08 PM

$TNXP

0 · Reply

Stino715pro Apr. 28 at 12:36 PM

$TNXP to Time, if someone is saying to you that you have to jump in the river, you will do that! 1 week it is sell Tonix and 2 day’s later you have to buy snd them sell again, seriously 😧

0 · Reply

Pipipopopipi Apr. 28 at 12:36 PM

$TNXP another 3% down and it’s not even open yet. Must be because strait of hormutz, chat gpt slowdown or opec news!!!. Just normal

0 · Reply

TheUnmaker Apr. 28 at 12:36 PM

$TNXP Thats alot of PM volume.

0 · Reply

ACMTrader Apr. 28 at 12:34 PM

$TNXP 💎💎

0 · Reply

TOOKPROFITS Apr. 28 at 12:16 PM

$TNXP of course it's a sell. seth is dumping again and the delusionals are buying the dip. How ridiculous is that

0 · Reply

TimeForChangeNow Apr. 28 at 12:11 PM

$TNXP Wall Street Zen Downgrades Tonix Pharmaceuticals (NASDAQ:TNXP) to Sell - Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Sunday... A SELL BULLS A SELL!

0 · Reply

Pipipopopipi Apr. 28 at 11:59 AM

$TNXP well the drop started earlier today

0 · Reply

auris Apr. 28 at 11:40 AM

$TNXP

0 · Reply

Stockeye2 Apr. 28 at 11:01 AM

$TNXP 💎

0 · Reply

Joe676 Apr. 28 at 10:56 AM

$TNXP

0 · Reply

beachbroke Apr. 28 at 10:32 AM

$TNXP

0 · Reply

FrankGelbert Apr. 28 at 8:11 AM

$TNXP JuggernautRaider, you are right, I am very optimistic. We will see what is confirmed by the numbers...

0 · Reply

TOOKPROFITS Apr. 28 at 6:29 AM

$TNXP this thing moves a nickel and the delusionals go crazy. I swear Seth has his own cult

0 · Reply

JuggernautRaider Apr. 28 at 2:42 AM

$TNXP the path to a $16M, 17M, or $18M quarter isn’t far. Maybe the migrane franchise does $3M, and additional inventory stocking at the end of Q1 (in anticipation of a price increase in which case the distributors would make MORE MONEY by stockpiling before the end of March as they can then get reimbursed at the higher price in April if an increase occurred)… then that gets you up to $17-18M assuming the 1.7x multiplier holds. Looking forward to a huge Q2! 🚀

0 · Reply

Market Cap	169.04M
Revenue (ttm)	13.11M
Net Income (ttm)	-124.02M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-946.00%
Debt to Equity Ratio	0.00

Volume	237,800
Avg Vol	415,244
Day's Range	N/A - N/A
Shares Out	13.41M
Stochastic %K	12%
Beta	1.75
Analysts	Strong Sell
Price Target	$54.33